National Institute of Biomedical Imaging and Bioengineering; Notice of Meeting, 49387 [2020-17678]
Download as PDF
<![CDATA[
Federal Register / Vol. 85, No. 157 / Thursday, August 13, 2020 / Notices
communication/messaging networks,
research, training, and subject matter
expertise. The dissemination of critical
COVID–19 information for tribal
communities builds trust, credibility,
and integrity of promoting a culturally
sensitive public health approach around
the information.
2. The JHU CAIH is uniquely
positioned to provide culturally specific
subject matter expertise drawn from a
direct care services or ‘‘boots on the
ground’’ approach. The CAIH has nearly
40 years of collaboration with Native
American tribes and supports public
health interventions in more than 140
tribal communities in over 21 states.
The breadth of knowledge and existing
partnerships will enhance
dissemination of information nationally.
Legislative Authority: The Snyder Act,
25 U.S.C. Section 13; the Indian Health
Care Improvement Act, 25 U.S.C.
Section 1621b; and Coronavirus Aid,
Relief, and Economic Security (CARES)
Act, Public Law 116–136.
FOR FURTHER INFORMATION CONTACT:
Audrey Solimon at Audrey.Solimon@
ihs.gov or by telephone at 301–590–
5421.
Michael D. Weahkee,
RADM, Assistant Surgeon General, U.S.
Public Health Service, Director, Indian Health
Service.
[FR Doc. 2020–17516 Filed 8–12–20; 8:45 am]
BILLING CODE 4165–16–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
Council for Biomedical Imaging and
Bioengineering.
The meeting will be open to the
public by videocast as indicated below.
The meeting will be closed to the public
in accordance with the provisions set
forth in sections 552b(c)(4) and
552b(c)(6), Title 5 U.S.C., as amended.
The grant applications and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
VerDate Sep<11>2014
17:16 Aug 12, 2020
Jkt 250001
Name of Committee: National Advisory
Council for Biomedical Imaging and
Bioengineering.
Date: September 15, 2020.
Open: 12:00 p.m. to 3:00 p.m.
Agenda: Report from the Institute Director
and other Institute Staff.
Place: National Institutes of Health,
Democracy II, 6707 Democracy Boulevard,
Bethesda, MD 20892 (Virtual Meeting).
Closed: 3:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Democracy II, 6707 Democracy Boulevard,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: David T. George, Ph.D.,
Associate Director, Office of Research
Administration, National Institute of
Biomedical Imaging and Bioengineering,
6707 Democracy Boulevard, Room 920,
Bethesda, MD 20892, georged@mail.nih.gov.
Any interested person may file
written comments with the committee
by forwarding the statement to the
Contact Person listed on this notice. The
statement should include the name,
address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
www.nibib1.nih.gov/about/NACBIB/
NACBIB.htm, where an agenda and any
additional information for the meeting
will be posted when available.
49387
listed in the Supplementary Information
section of this notice. Upon expiration
of the evaluation period the granted
licenses may be converted into a fully
exclusive patent commercialization
license for the term of the last to expire
of the patent estate upon the company
providing NHLBI with a commercial
development plan supporting such a
conversion. This notice is intended to
apprise the public of a aforementioned
license and provide a fifteen (15) day
notice period for the objection.
DATES: Only written comments and/or
applications for a license which are
received by the National Heart, Lung,
and Blood Institute on or before August
28, 2020 will be considered.
ADDRESSES: Requests for copies of
patent applications (electronic only),
inquiries, and comments relating to the
contemplated an exclusive patent
license should be emailed to: Michael
Shmilovich, Esq., Senior Licensing and
Patent Manager, 31 Center Drive Room
4A29, MSC2479, Bethesda, MD 20892–
2479, phone number 301–435–5019
shmilovm@nih.gov.
SUPPLEMENTARY INFORMATION:
Intellectual Property (Patent Estate)
HHS Ref. No. E–036–2015–0 and –1,
U.S. Provisional Patent Application 62/
079,975 filed November 14, 2014
Dated: August 7, 2020.
(expired), International Patent
Miguelina Perez,
Application PCT/US2015/060646 filed
Program Analyst, Office of Federal Advisory
November 13, 2015 (nationalized), U.S.
Committee Policy.
Patent Application 15/525,921 having
[FR Doc. 2020–17678 Filed 8–12–20; 8:45 am]
an effective filing date of November 13,
2015, and U.S. Divisional Patent
BILLING CODE 4140–01–P
Application 16/985,797 filed August 5,
2020, any and all continuation or
DEPARTMENT OF HEALTH AND
divisional applications claiming priority
HUMAN SERVICES
to any of the above.
The patent rights in these inventions
National Institutes of Health
have been assigned or exclusively
licensed to the Government of the
Prospective Grant of an Exclusive
United States of America.
Start-Up Patent License for Evaluation:
The prospective exclusive license
Immunotherapy for Relapsed/
territory may be worldwide and in field
Refractory Diffuse Large B Cell
of use that may be limited to
Lymphoma
Immunotherapy against relapsed or
refractory diffuse large B cell
AGENCY: National Institutes of Health,
lymphoma, and where the ‘‘Licensed
Health and Human Services (HHS).
Products’’ may be defined to be limited
ACTION: Notice.
to transgenically modified allogeneic
SUMMARY: The National Heart, Lung, and natural killer cells within the scope of
Blood Institute, of the National
the Licensed Patent Rights that
Institutes of Health, Department of
transiently express one or more of a (1)
Health and Human Services, is
CCR7 receptor, (2) CD16a (HA–CD16),
contemplating the grant of an exclusive
(3) a DR5 specific TRAIL, or (4) CD19
start-up patent license for evaluation to
chimeric antigen receptor.
The aforementioned patent estates
ONK Therapeutics, a start-up company
spun-off from the National University of cover methods of treating a subject with
Ireland Galway, and incorporated under a tumor by administering transgenically
modified adoptive NK (natural killer
the laws of the Republic of Ireland, to
cells), methods of generating transgenic
practice, for a limited time, the
NK cells, and transgenic NK cells per se.
inventions covered by the patent estate
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
E:\FR\FM\13AUN1.SGM
13AUN1
]]>Agencies
[Federal Register Volume 85, Number 157 (Thursday, August 13, 2020)]
[Notices]
[Page 49387]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-17678]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical Imaging and Bioengineering;
Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the National Advisory
Council for Biomedical Imaging and Bioengineering.
The meeting will be open to the public by videocast as indicated
below. The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications and/or contract proposals, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: National Advisory Council for Biomedical
Imaging and Bioengineering.
Date: September 15, 2020.
Open: 12:00 p.m. to 3:00 p.m.
Agenda: Report from the Institute Director and other Institute
Staff.
Place: National Institutes of Health, Democracy II, 6707
Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).
Closed: 3:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Democracy II, 6707
Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: David T. George, Ph.D., Associate Director,
Office of Research Administration, National Institute of Biomedical
Imaging and Bioengineering, 6707 Democracy Boulevard, Room 920,
Bethesda, MD 20892, [email protected].
Any interested person may file written comments with the committee
by forwarding the statement to the Contact Person listed on this
notice. The statement should include the name, address, telephone
number and when applicable, the business or professional affiliation of
the interested person.
Information is also available on the Institute's/Center's home
page: https://www.nibib1.nih.gov/about/NACBIB/NACBIB.htm, where an
agenda and any additional information for the meeting will be posted
when available.
Dated: August 7, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-17678 Filed 8-12-20; 8:45 am]
BILLING CODE 4140-01-P
